Form 4: Apellis CMO Sells Shares for Tax Withholding

Apellis Pharmaceuticals' Chief Medical Officer, Caroline Baumal, sold 2,797 shares of common stock to cover tax obligations related to RSU vesting.

Summary

• Caroline Baumal, Chief Medical Officer and Director of Apellis Pharmaceuticals, Inc. (APLS), reported a transaction on January 22, 2026.
• The transaction involved the sale of 2,797 shares of Apellis Pharmaceuticals Common Stock.
• The shares were sold at a price of $21.7654 per share.
• The purpose of this sale was to cover tax withholding obligations associated with Restricted Stock Units (RSUs) that were released on January 21, 2026.
• Following this transaction, Caroline Baumal beneficially owns 86,527 shares of Common Stock directly.

Sentiment

Score: 5

Explanation: The filing reports a routine, non-discretionary sale of shares by an insider to cover tax withholding on RSU vesting. This type of transaction is neutral in sentiment as it does not reflect a discretionary investment decision or a change in the insider's outlook on the company.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This is a routine insider transaction, common across all industries, particularly in biotech and pharmaceutical companies where executive compensation often includes Restricted Stock Units (RSUs). The sale to cover tax withholding is a standard, non-discretionary event upon RSU vesting.

Comparison to Industry Standards

• The sale of shares to cover tax withholding upon RSU vesting is a standard and widely accepted practice for executives across publicly traded companies, including those in the biotechnology sector.
• This type of transaction is generally considered non-discretionary and is often pre-arranged under Rule 10b5-1 plans, which are common mechanisms for insiders to manage their equity compensation in compliance with insider trading regulations.

Stakeholder Impact

• Shareholders: Minimal to no direct impact as this is a routine, non-discretionary transaction for tax purposes and does not signal a change in management's confidence or company fundamentals.
• Employees: No direct impact.

Key Dates

Recommendation

This Form 4 reports a non-discretionary sale of shares by a company officer solely to cover tax withholding obligations related to RSU vesting. Such transactions are routine and do not typically indicate a change in management's outlook or a strategic shift, thus warranting no change to an existing 'hold' recommendation.

Keywords

Apellis Pharmaceuticals, APLS, Form 4, Insider Transaction, Stock Sale, Tax Withholding, RSU Vesting, Caroline Baumal, Chief Medical Officer